NICU Parenteral Information

Based on medications as available for use within NICU
For neonates cared for outside of NICU/Family Newborn Care, refer to Pediatric Parenteral Information

Search Another Drug

morphine

Analgesics and Antipyretics
HIGH ALERT

Reserved/Restricted : Extended release capsules- prescribing and management is restricted to prescribers with Pediatric Acute Pain Service (APS), Pediatric Advanced Care Team (PACT), and hematology/oncology.

  • Supplied as morphine sulfate
Go to Neonatal Drug Dosing Guideline for morphine
Administration Information
IV Direct- Doses less than 1 mg
Standard Concentration
0.4 mg/mL
Administration Duration
00:05 (hh:mm)

IV Direct- Doses greater than 1 mg
Standard Concentration
2 mg/mL [Supplied in Standard Concentration]
Administration Duration
00:05 (hh:mm)

IV Continuous Infusion- Patients less than or equal to 2 kg with D5W as diluent
Standard Concentration
0.15 mg/mL
Monitoring Drug specific monitoring parameters have been approved by the IWK Drugs & Therapeutics Committee. They are assigned to select medications using the <a href='https://www.dir.iwk.nshealth.ca/Content/resources/ParenteralMonitoringGuidelinesRevised.pdf' target='_blank' class='text-warning'>BC Children's Hospital monitoring Levels 1 through 4</a>, these are currently approved <strong>recommendations</strong> for monitoring. An IWK monitoring policy is in development that, once approved, will it guide prescribers and nursing staff through expectations of these monitoring levels. Once the policy is approved, appropriate education and training provided and any necessary equipment is procured, adherence to these drug specific monitoring parameters will be required for all patients receiving medications in the manner described. Until these significant milestones are reached, please continue to follow IWK care area specific practices for monitoring patients.
As per clinical order set IWK MOCO
Comment

When continuous infusion is running, bolus (intermittent) doses can be administered over 5 minutes using "BOLUS" function.
Bolus may be administered over seconds in critical care areas.


IV Continuous Infusion- Patients greater than 2 kg with D5W as diluent
Standard Concentration
1 mg/mL
Monitoring Drug specific monitoring parameters have been approved by the IWK Drugs & Therapeutics Committee. They are assigned to select medications using the <a href='https://www.dir.iwk.nshealth.ca/Content/resources/ParenteralMonitoringGuidelinesRevised.pdf' target='_blank' class='text-warning'>BC Children's Hospital monitoring Levels 1 through 4</a>, these are currently approved <strong>recommendations</strong> for monitoring. An IWK monitoring policy is in development that, once approved, will it guide prescribers and nursing staff through expectations of these monitoring levels. Once the policy is approved, appropriate education and training provided and any necessary equipment is procured, adherence to these drug specific monitoring parameters will be required for all patients receiving medications in the manner described. Until these significant milestones are reached, please continue to follow IWK care area specific practices for monitoring patients.
As per clinical order set IWK MOCO
Comment

When continuous infusion is running, bolus (intermittent) doses can be administered over 5 minutes using "BOLUS" function
Bolus may be administered over seconds in critical care areas.


Subcutaneous
Standard Concentration
2 mg/mL [Supplied in Standard Concentration]
Compatibility Information
Compatible Solutions
0.45% Sodium Chloride (NaCl), 0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)
Drug–Drug (Y–Site) or Drug–IV Solution Compatibility
Refer to Micromedex IV Compatibility
Go to Pediatric Parenteral Administration Information for morphine
Created on August 02, 2019 04:42 PM
Updated on October 11, 2024 08:38 AM

Go Back